Age dependency of cardiovascular outcomes with the amyloidogenic p142I transthyretin variant among black individuals

Back

HFA Premium Access

Age dependency of cardiovascular outcomes with the amyloidogenic p142I transthyretin variant among black individuals

Session: Cardiac amyloidosis from epidemiology to treatment

Topic: Epidemiology, Prognosis, Outcome

Speaker: Doctor S. Selvaraj (Durham, US)

Event: Heart Failure 2023

Congress Presentation

About the speaker

Doctor Senthil Selvaraj

Duke University School of Medicine, Durham (United States of America)

2 presentations

0 follower

4 more presentations in this session

Demographic characteristics and clinical follow-up of the 2788 transthyretin amyloid cardiomyopathy patients treated with tafamidis during the French Early Access Program (RTU)

Speaker: Professor J. Inamo (Fort de France, MQ)

Prevalence and characteristics of transthyretin amyloid cardiomyopathy in patients with left ventricular hypertrophy: final analysis of the TTRACK study

Speaker: Professor N. Piriou (Nantes, FR)

Tracking treatment response in cardiac AL amyloidosis with native-T1 mapping

Speaker: Doctor A. Ioannou (Greater London, GB)

Effect of patisiran treatment in patients with hATTR amyloidosis with cardiomyopathy and polyneuropathy: post-hoc analysis of the APOLLO-B study

Speaker: Professor F. Gustafsson (Copenhagen, DK)

Access the full session

Cardiac amyloidosis from epidemiology to treatment

Speakers: Doctor S. Selvaraj, Professor J. Inamo, Professor N. Piriou, Doctor A. Ioannou, Professor F. Gustafsson

Access

Video

About the event

Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations

Congress

Age dependency of cardiovascular outcomes with the amyloidogenic p142I transthyretin variant among black individuals

About the speaker

Doctor Senthil Selvaraj

4 more presentations in this session

Demographic characteristics and clinical follow-up of the 2788 transthyretin amyloid cardiomyopathy patients treated with tafamidis during the French Early Access Program (RTU)

Prevalence and characteristics of transthyretin amyloid cardiomyopathy in patients with left ventricular hypertrophy: final analysis of the TTRACK study

Tracking treatment response in cardiac AL amyloidosis with native-T1 mapping

Effect of patisiran treatment in patients with hATTR amyloidosis with cardiomyopathy and polyneuropathy: post-hoc analysis of the APOLLO-B study

Access the full session

Cardiac amyloidosis from epidemiology to treatment

About the event

Heart Failure 2023

ESC 365 is supported by